
Over the course of the first six months of 2022, Sanofi expects to submit the first regulatory application for marketing authorization for a possible treatment of respiratory syncytial virus (RSV) in infants.
In a press release, the company states that it has received results from a phase II/III trial of the drug nirsevimab, which supports the drug candidate.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app